CTNM

Equibles Rating blended score · not investment advice

Overall

Neutral

Technical · trend & momentum Strong Buy

◦ 50 / 200-day cross no cross

+ Price vs 200-day avg +20% above

+ Price vs 50-day avg +15% above

◦ RSI (14) 63 · neutral

+ MACD trend positive

+ 52-week position 86% · near high

Sentiment · smart money Neutral

◦ Trend (MA cross) 50d $13 › 200d $13 — 50d above 200d

+ Institutional flow +13% holders QoQ · +22 funds added

− Insider flow Net -$109.6K over 90 days · 100% sells

− Short interest 4.43% of float · ▲ +15.6% MoM · 7.6 days cover

◦ Volume signal Volume near normal

+ Institution breadth 90 holders — near 2-yr high, broad support

Fundamentals Weak

− Revenue growth −100% Y/Y

◦ EPS growth +0% Y/Y

− Free cash flow $-55.5M

+ Balance sheet net cash $75.6M

Blended from price, positioning & fundamentals · daily-close · not investment advice.

Up next

Next earnings call

Jul 29, 2026 Est · unconfirmed · in 3 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 5, 2026

Technicals

trend & momentum for long-term holders Strong Buy

0 · 2 · 4

50 / 200-day cross

no cross Neutral

Price vs 200-day avg

+20% above Bullish

Price vs 50-day avg

+15% above Bullish

RSI (14)

63 · neutral Neutral

MACD trend

positive Bullish

52-week position

86% · near high Bullish

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $13 › 200d $13 — 50d above 200d

Institutional flow Accumulating

+13% holders QoQ · +22 funds added

Insider flow Distributing

Net -$109.6K over 90 days · 100% sells

Short interest Rising

4.43% of float · ▲ +15.6% MoM · 7.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

90 holders — near 2-yr high, broad support

Price context

position in its 52-week range

52-wk low $4 Now $15 · 86% 52-wk high $17

vs 200-day avg +20% vs 50-day avg +15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
CTNM Contineum Therapeutics, Inc. this stock	$644.97M	+32.1%	-100.0%	—	4.4%
AKTX Akari Therapeutics Plc	$953.21B	-9.9%	—	—	0.0%
ONC BeOne Medicines Ltd.	$470.30B	-2.0%	+22179.2%	957.1	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$134.02B	+16.5%	+46.2%	31.3	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$69.80B	-15.1%	+20.8%	16.3	3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

% held: 81.8%
Net QoQ: +940.2K sh
Top holder: SUVRETTA CAPITAL MANAGEME…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Rising

Shares short

1.7M

Days to cover: 7.6d
Change: +223.4K sh

View

Short Volume

Short vol %

54%

As of: Jul 2, 2026

Short Total

View

Fails to Deliver

FTD shares

551

Value: $6.8K
As of: Jun 5, 2026

View

Off-Exchange

Off-exchange %

62.0%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$109.6K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Financials

Revenue (FY)

Net income (FY): $-60.0M
EPS diluted: $-2.17

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Jun 30, 2026
This year: 9

View

Proposed Sales

Value

$156.0K

Shares: 9.5K
Filed: Jul 1, 2026

View

Earnings & Events

Earnings Calls

Last call

Jun 9, 2026

View

Performance

	5D	20D	120D	MTD	YTD
CTNM	+13.0%	+21.0%	+64.7%	-7.9%	+32.1%
SPY	+1.4%	-1.3%	+8.0%	-0.3%	+9.2%
vs SPY	+11.6%	+22.2%	+56.7%	-7.6%	+22.9%

Price & Indicators

Technicals

Versus peers

At a glance

Performance